Findings

What do systematic reviews say?

74 questions · 76 findings · 8 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 31 · 40.8%GRADE not reported 7 · 9.2%Very low 17 · 22.4%Low 11 · 14.5%Moderate 9 · 11.8%High 1 · 1.3%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Related · question page
- Macrolide+tetracycline vs macrolide · Lung function (trough FEV1) Change from baseline to 12 weeks (end of active treatment)
  Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 182 participants
  Very low
Related · question page
- Carbonic anhydrase inhibitors vs inactive control · Cardiovascular mortality
  Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
  OR 0.21 [0.02, 2.48]
  1 study · 18 participants
  Very low
Related · question page
- Methylxanthine derivatives vs inactive control · Cardiovascular mortality
  Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Related · question page
- Methylxanthine derivatives vs inactive control · cAHI
  Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 15 participants
  Very low
Related · question page
- Methylxanthine derivatives vs inactive control · AHI
  Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 15 participants
  Very low

Macrolide+tetracycline vs macrolides

Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 182 participants
Very low

Carbonic anhydrase inhibitors vs inactive control

cAHI · adults with central sleep apnoea associated with heart failure

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Anxiolytics vs inactive control

Cardiovascular mortality · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anxiolytics vs inactive control

Serious adverse events · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anxiolytics vs inactive control

Quality of sleep · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anxiolytics vs inactive control

Quality of lifeÂ · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anxiolytics vs inactive control

AHI · adults with central sleep apnoea associated with heart failure

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
GRADE not reported

Anxiolytics vs inactive control

All‐cause mortality · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methylxanthine derivatives vs inactive control

cAHI · adults with central sleep apnoea associated with heart failure

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Very low

Methylxanthine derivatives vs inactive control

Cardiovascular mortality · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methylxanthine derivatives vs inactive control

Serious adverse events · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methylxanthine derivatives vs inactive control

Quality of sleep · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Carbonic anhydrase inhibitors vs inactive control

Cardiovascular mortality · adults with central sleep apnoea associated with heart failure

It is very uncertain whether carbonic anhydrase inhibitors changes cardiovascular mortality compared with inactive control (very low certainty).

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
OR 0.21 [0.02, 2.48]
1 study · 18 participants
Very low

Methylxanthine derivatives vs inactive control

Quality of life · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methylxanthine derivatives vs inactive control

AHI · adults with central sleep apnoea associated with heart failure

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 15 participants
Very low

Methylxanthine derivatives vs inactive control

All‐cause mortality · adults with central sleep apnoea associated with heart failure

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypnotics vs inactive control

cAHI · adults with primary central sleep apnoea

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 5 participants
GRADE not reported

Hypnotics vs inactive control

Cardiovascular mortality · adults with primary central sleep apnoea

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypnotics vs inactive control

Serious adverse events · adults with primary central sleep apnoea

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypnotics vs inactive control

Quality of sleep · adults with primary central sleep apnoea

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for central sleep apnoea in adults 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found